Goldman Sachs Adjusts Rapport Therapeutics Price Target

Goldman Sachs analyst Salveen Richter has reaffirmed a 'Buy' rating on Rapport Therapeutics, Inc. (RAPP) and increased the price target from $62 to $68. This change indicates a positive revision in the analyst's assessment of the company's valuation and market standing.